KAT6A and neoplasm: To investigate the role of KAT6A in PARPi resistance in ovarian cancer, we collected both primary and PARPi‐resistant tumor tissues from seven patients with ovarian cancer (patients 1–4 with BRCA deficiency were treated with olaparib, and patients 5–7 without BRCA deficiency were treated with niraparib according to the National Comprehensive Cancer Network [NCCN] guidelines, nccn.org/patients).